NCT02830477 - "Study Evaluating Real World Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis" | Biotech Hunter

Enrollment

313

Participants

Timeline

Start Date

October 14, 2016

Primary Completion Date

December 1, 2020

Study Completion Date

March 1, 2021

Conditions

Hemophilia A, Congenital

Interventions

BIOLOGICAL

Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973

unmodified, full length recombinant FVIII

Trial Locations (25)

Children's Rehabilitation Services/ University of South Alabama, Mobile

University of Colorado Hemophilia and Thrombosis Center, Aurora

University of Florida Health Cancer Center, Gainesville

Nemours Children's Clinic - Division of Pediatric Hematology/Oncology - Jacksonsville, Jacksonville

Nemours Children's Clinic - Pensacola, Pensacola

Henry Ford Hospital Adult Hemophilia and Thrombosis Treatment Center, Detroit

Washington University Center for Bleeding and Blood Clotting Disorders, St Louis

Hemophilia Center of Western New York, Buffalo

East Carolina University - Brody School of Medicine, Greenville

Wake Forest University School of Medicine, Winston-Salem

Children's Hospital at OU Medical Center, Oklahoma City

Intermountain Hemophilia & Thrombosis Center, Salt Lake City

Comprehensive Center for Bleeding Disorders / Blood Center of Wisconsin, Milwaukee

Multiple Locations